Tenapanor Hydrochloride
- Generic Name
- Tenapanor Hydrochloride
China Approves First-in-Class Tenapanor for Hyperphosphatemia in Dialysis Patients
• Fosun Pharma's Wan Ti Le (tenapanor hydrochloride tablets) has received NMPA approval for controlling serum phosphorus in dialysis patients with chronic kidney disease who have inadequate response to phosphate binders.
• As the world's first and only approved phosphate absorption inhibitor, tenapanor works through a novel mechanism by inhibiting NHE3, reducing intestinal phosphate absorption through the paracellular pathway.
• Clinical studies show tenapanor can decrease serum phosphate levels by an additional 0.57 mmol/L when combined with phosphate binders, potentially addressing the low phosphate control rates (39%) among China's one million hemodialysis patients.
Breakthroughs in Biotech: Promising Developments in Diabetes, Cancer, and Lymphoma Treatments
Recent advancements in the biotech sector highlight significant progress in treatments for diabetes, breast cancer, multiple myeloma, and T cell lymphoma, with several companies receiving FDA approvals or making notable strides in clinical trials.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath